article

Expert view: Are you ready for next generation therapeutic antibodies?

Posted: 24 March 2020 | | No comments yet

Do not let the challenges of selecting and analysing bispecific antibodies create havoc in your antibody development.

The biotherapeutics landscape is moving fast towards molecules with higher potency and greater efficiency than ever before. The rise and growth of bispecific antibodies (bsAbs) has fuelled this move; mainly due to their capability of binding to two antigens at the same time, thereby increasing therapeutic efficacy and decreasing the need for large production volumes. However, with about 100 different formats of bsAb currently under development, selecting, analysing and purifying the best candidate for therapeutic drug development presents multiple challenges.











To read this expert view in full, please complete the form below. By clicking submit you confirm that you accept our terms and conditions and privacy policy.


*

*

*

*

*

*

*

*

This content is provided to you for free thanks to the kind support of our sponsors: ForteBio

Related organisations

Send this to a friend